Browse all practice questions for the Pharmaceutics Drug Disposition Practice Test. Search by topic, open any question and review its full explanation, then test yourself in the practice quiz.

Pharmaceutics Drug Disposition Practice Test course image
More practice questions

These questions are part of the practice quiz. Start practicing

  • True or false: If a drug has an active metabolite, it is likely that plasma concentration does not correlate with response.
  • Which option best defines 'site of absorption' in pharmacokinetics?
  • How can you estimate the elimination rate constant (ke) and half-life (t1/2) from an IV concentration-time profile?
  • Which of the following is an example illustrating that an endogenous compound can act as a xenobiotic?
  • For intravenous administration, what is the bioavailability F?
  • In a constant IV infusion, how does the concentration change over time?
  • What characterizes nonlinear (saturable) pharmacokinetics, and can you name a classic drug example?
  • Which equation best represents the relationship between ke and t1/2 in a first-order elimination process?
  • If the concentration-time curve shows a decreasing trend, what does this indicate about the rates of absorption and elimination?
  • What is the site of administration in pharmacokinetics?
  • Which kinetic order is defined by a constant amount of drug being removed per unit of time?
  • In a semi-log plot of concentration versus time for a drug with elimination, what does the slope primarily indicate?
  • Define intrinsic clearance (CLint) and describe how it is measured in vitro.
  • Which statement accurately describes ADME in pharmacokinetics?
  • Which renal clearance processes are the main routes of urinary drug elimination?
  • Is it true that some endogenous compounds can act as xenobiotics?
  • In first-order kinetics, the magnitude of a drug's effect is best described as related to which statement?
  • Which statement about regulatory bioequivalence criteria is accurate?
  • On a concentration-effect curve, the plateau of the effect corresponds to the therapeutic effect.
  • Which of the following sets lists formulation strategies used to improve solubility and dissolution rate of poorly soluble drugs?
  • Which statement best describes IVIVC and its value in formulation development and regulatory submissions?
  • True or False: A drug exhibiting a quantal response may be irreversible.
  • The rate of drug elimination by the kidney at 1000x concentration is the same as at 1x concentration.
  • Define hepatic extraction ratio (E) and explain its implications for flow-limited versus capacity-limited clearance.
  • Time delays between pharmacokinetic changes and pharmacodynamic response can lead to ...
  • When may response-time curves be more useful than concentration-time curves?
  • Most kinetic processes in the body follow which order of kinetics?
  • Which concentration-time profile describes an IV bolus administration?
  • If the toxic dose to produce a response (TD50) is 25 mg and the dose for a desired effect (ED50) is 5 mg, the TI is 5.
  • For a drug following first-order elimination, the shape of the concentration-time curve remains identical when dose is scaled by 1x, 10x, or 100x for the same route of administration.
  • Which factor would you monitor to predict response for drugs with active metabolites?
  • Which type of drugs are likely to have an instantaneous effect?
  • TI reflects the safety margin between therapeutic and toxic doses.
  • How does first-pass hepatic metabolism affect oral bioavailability, and which drugs show the greatest loss?
  • Explain why plasma concentration of drugs with enantiomers does not correlate with response.
  • IV Bolus vs Constant Infusion: Which statement describes IV bolus administration?
  • Which pharmacokinetic metric is most directly related to overall drug exposure in the body?
  • What does MEC stand for?
  • What is the linear form of the first-order kinetics equation?
  • Drug X is more active when given orally than when given IV. What can this indicate?
  • Why is plasma concentration used to predict drug effect?
  • Which statement best describes a quantal dose-response relationship?
  • What PK considerations are relevant when dosing in obesity, and what modeling approach is commonly used to address them?
  • The area under the concentration-time curve (AUC) represents what?
  • Which sequence correctly describes the path of an orally administered drug from ingestion to excretion?
  • For inhaled drugs, which statement best describes the determinants of systemic exposure?
  • Xenobiotic is best defined as
  • Which serves as the conduit delivering drug from the site of administration to tissues?
  • In pharmacokinetics, two major concentration gradients are between which two sites?
  • The negative slope of a concentration-time curve is also known as which of the following?
  • For poorly soluble drugs taken orally, what step is typically rate-limiting for absorption?
  • In a semi-log plot, if the line is steep, what does that indicate about elimination rate?
  • Why are pediatric PK dosing regimens often based on weight or body surface area, and what PK principles underlie this practice?
  • Why does warfarin take a couple of days to have its full effect?
  • Which of the following is a case where plasma concentration does NOT correlate with pharmacologic response?
  • In an IV bolus administration, how does plasma concentration change over time?
  • Why does zero-order elimination lead to accumulation with increasing dose?
  • Which antibiotic does not have concentration-dependent killing?
  • Besides blood, which sample type is listed as a potential data source for concentration-time profiling?
  • In the linear form of first-order kinetics, what is the slope of log C versus time?
  • What effect does hepatic impairment typically have on hepatic clearance?
  • If a drug is absorbed into the blood but is inactivated before reaching the site of action, which statement best describes this scenario?
  • What is the primary PK objective of extended-release formulations?
  • A large TI indicates higher safety.
  • Which of the following is a pharmacokinetic mechanism contributing to tolerance?
  • What does a larger area under the concentration-time curve (AUC) indicate about systemic exposure?
  • How do PK and PD integrate in PK/PD models to inform dosing decisions?
  • For IV administration, which relation describes how AUC depends on Dose and clearance?
  • Which statement correctly describes Cmax?
  • What does it mean by 'less negative elimination slope'?
  • A larger TI implies a wider safety margin between therapeutic and toxic doses.
  • The effect of a drug on target cells is known as
  • During intermittent IV infusion, what determines the peak and trough concentrations, and how does this relate to clearance?
  • What is enterohepatic recirculation, and what pharmacokinetic pattern might indicate its presence?
  • Under what circumstances is a loading dose recommended, and what is its primary purpose?
  • If a drug has a high hepatic extraction ratio, what is the likely effect on its oral bioavailability?
  • Which term describes the tissue where a drug exerts its action?
  • For concentration-dependent antibiotics, using larger, less frequent doses is often more effective.
  • How would you modify dosing for a renally cleared drug in a patient with severe renal impairment?
  • In a chiral drug with active S-enantiomer, why might total plasma concentration fail to predict effect?
  • A positive slope on a concentration-time curve indicates what pharmacokinetic situation?
  • Plasma concentration does not correlate with response in single-dose therapy.
  • Which statement best explains why oral administration can be more pharmacologically active for certain prodrugs than IV administration?
  • Which fate describes a free drug that becomes sequestered in other tissues with no immediate effect?
  • Which statement best describes the concentration-time plot for zero-order elimination?
  • The therapeutic index (TI) is defined as the ratio of the dose needed to produce a toxic effect to the dose needed to elicit the desired therapeutic response.
  • In the well-stirred hepatic clearance model, CLint represents what?
  • How is oral bioavailability defined, and how does it compare to intravenous exposure?
  • In a quantal dose-response assessment, which of the following is a typical endpoint?
  • A peak or horizontal line on the curve signifies what?
  • Which statement about in vitro models used to predict in vivo absorption is most accurate?
  • What pharmacokinetic pattern would most strongly suggest enterohepatic recirculation besides secondary peaks?
  • ADME is best described as the study of pharmacokinetics.
  • Which parameter remains constant across different doses in zero-order kinetics?
  • What are the two main types of plasma concentration versus effect curves?
  • Which factor would shift a concentration-time curve downward (lower plasma levels)?
  • Why may there be a time delay even if the drug is fully absorbed?
  • In predicting intestinal absorption, which statement is most accurate?
  • Why is the unbound drug fraction the one that can be distributed and cleared?
  • How is the volume of distribution defined, and what does an apparent Vd much larger than body water imply?
  • Which statement correctly distinguishes absorption from distribution?
  • In first-order kinetics, the half-life depends on the percentage of drug remaining.
  • A concentration-time curve that starts at a high concentration and declines monotonically is most indicative of which route of administration?
  • Which term describes a drug response that is all-or-none and typically plotted as the fraction of a population showing an effect?
  • Which statement about graded responses is true?
  • Which statement best describes quantal responses?
  • The magnitude of a drug's response is proportional to its concentration at which site?
  • Which statement best describes IVIVC in formulation development?
  • What happens to the elimination rate in first-order kinetics as drug concentration falls?
  • If the target for a drug is H. pylori in the stomach, which strategy would lead to higher success?
  • Which statement best describes zero-order elimination?
  • A plot of log concentration versus time that is linear indicates which type of kinetics?
  • Which administration route provides an immediate peak concentration by bypassing absorption phase?
  • In regulatory bioequivalence studies, which PK parameters are primarily compared between products, and what is the typical acceptance range?
  • How does the elimination rate change as concentration increases for first-order and zero-order kinetics?
  • Which formulation strategy is commonly used to improve solubility by converting a drug into an amorphous solid dispersion?
  • The drug response is related to plasma concentration due to equilibrium. Which statement best describes this relationship?
  • Which statement accurately describes MEC and MTC in relation to therapeutic and toxic effects?
  • Decreased concentration of drug at the target site is an example of tolerance mechanism.
  • Which PK metric corresponds to the peak drug concentration after an oral dose when comparing multiple candidates?
  • Which scenario supports that a drug is a prodrug?
  • True or False: A semi-log plot makes a zero-order kinetics equation appear as a straight line.
  • Which statement about MEC and therapeutic response is true?
  • In noncompartmental analysis (NCA) of PK data, which metrics are typically used to summarize oral drug disposition?
  • Side effects arise because drugs distribute to non-target tissues during transit from administration to action.
  • What in vitro tests can help predict in vivo intestinal absorption, and what is a common limitation of these tests?
  • A reduction in blood pressure with antihypertensives is an example of which type of response?
  • If dosing rate exceeds elimination capacity in zero-order kinetics, how does plasma concentration change over time?
  • The magnitude of therapeutic response is proportional to concentration of drug at which site?
  • __________ is the diminished response to same dosage of a drug, either developed slowly or acutely.
  • For zero-order kinetics, which graph shows a straight line as drug concentration changes over time?
  • Which PK parameter is commonly used to adjust dosing in hepatic impairment, and what does it reflect?
  • What is total body clearance (CL) and how is it calculated after IV administration?
  • How does urine pH influence ion trapping of weak acids and bases, and what is the clinical implication?
  • Which statement best describes zero-order elimination?
  • Pharmacokinetics describes
  • Which statement best describes the relationship between dose and onset?
  • Acquired resistance may be totally resistant in some bacteria or cancer cells.
  • If a drug has a high hepatic extraction ratio, what primarily limits its clearance?
  • How does drug partitioning into milk during lactation occur, and what PK considerations does it create for nursing infants?
  • Which in vitro system is used to measure liver intrinsic clearance (CLint)?
  • Which substances are absorbed in the stomach?
  • Which statement best describes the duration of action?
  • According to the vertical line test for a quantal-graded response curve, if the line does not bisect both the desired therapeutic effect and the adverse effects, the therapeutic index is larger.
  • Drugs bound to plasma proteins mainly affect which pharmacokinetic parameter?
  • Intensity of a drug's response is proportional to which variable?
  • For methotrexate, response relates most closely to which factor?
  • Regarding enantiomers, which statement is true?
  • Which type of response is elicited only when drug concentration exceeds a critical threshold?
  • What does the concentration-time graph look like for first-order versus zero-order elimination?
  • Why are metabolized drugs bound to albumin not considered in the concentration-time curve?
  • Under repeated dosing, which kinetic profile is most likely to lead to drug accumulation and toxicity?
  • For the concentration-effect curve, increasing dose from 1x to 10x to 100x does not change the curve shape for the same route.
  • In general, what determines the magnitude of the effect of a drug?
  • Why do many drugs have side effects?
  • What is downregulation?
  • Pharmacokinetic adaptations can alter absorption when food or drug interactions are present.
  • What is the primary determinant of the apparent volume of distribution for a drug that partitions strongly into tissues?
  • Which two properties does the Biopharmaceutics Classification System (BCS) classify drugs by, and how do they influence oral absorption?
  • Compared with oral administration, an intramuscular injection would shift the concentration-time curve in which direction?
  • What does a quantal dose-response curve measure?
  • Which response is known as an all-or-none response?
  • Which modeling approaches are commonly used to adjust pediatric dosing for growth and maturation?
  • Describe the well-stirred hepatic clearance model and identify its key variables.
  • After the stomach, absorption of most drugs continues primarily in which site?
  • Which type of kinetics is more likely to result in drug toxicity under repeated dosing?
  • Gentamicin's efficacy increases with higher peak concentrations; the statement is true.
  • How does an intravenous infusion alter the concentration-time profile compared with a bolus dose?
  • Which type of response is proportional to concentration and usually reversible?
  • Peak time (Tmax) is defined as which of the following?
  • In first-order kinetics, if 20 percent of the drug is removed every hour, how does the amount removed per hour relate to concentration?
  • Onset of action is defined as the time to reach MEC.
  • If a semi-log plot shows a negative slope and the slope is steeper than another, what does this indicate?
  • Which statement best defines the duration of action for a drug on a concentration-time graph?
  • What is nonlinear mixed-effects modeling (nlME) in population PK, and what is its major advantage?
  • If a drug does not have concentration-dependent killing, how will the dose-response curve look and what type of kinetics characterize it?
  • True or false: It is impossible to determine the total amount of drug present in the body by direct methods.
  • Doubling to 100x the dose would result in a longer half-life.
  • Allometric scaling in pharmacokinetics commonly uses which body size descriptor?
  • How does the half-life change in first-order versus zero-order kinetics?
  • Which statement describes the relationship between plasma concentration changes and tissue distribution?
  • In a linear plot of first-order kinetics (log C vs time), what does the y-intercept represent?
  • A peak in a concentration-time curve reflects what about the rates of absorption and elimination?
  • What regulatory bioequivalence acceptance criterion for AUC and Cmax is commonly used, and what is the rationale behind it?
  • Which matrix is commonly used to collect data for a concentration-time curve?
  • In a concentration-time curve, what does the x-axis represent?
  • Which is NOT listed as a route of drug elimination?
  • What factors largely determine systemic exposure for inhaled drugs intended for lung therapy?
  • What does MTC stand for?
  • What does the area under the concentration-time curve (AUC) represent in pharmacokinetics, and how is it related to clearance after intravenous administration?
  • Differentiate between one-compartment and two-compartment models in terms of their distribution phases.
  • Fluctuating antibiotic concentrations are sometimes more desirable than steady concentrations.
  • How many half-lives are typically needed to reach steady-state concentrations for most drugs?
  • Which statement about zero-order elimination is true?
  • Tolerance vs acquired resistance
  • How can patient covariates such as weight and renal function contribute to interindividual PK variability?
  • On a concentration-time graph, onset of action is best defined as the time to reach MEC.
  • How does the route of administration influence Tmax and overall absorption rate?
  • Which statement best describes zero-order kinetics?
  • How is bioequivalence typically assessed in regulatory studies, and what does the 80–125% acceptance window represent?
  • Which plot yields a straight line for first-order elimination?
  • In noncompartmental analysis, which metric is used to characterize the extent of drug exposure from time zero to infinity?
  • Which organ is the primary site of metabolism via portal circulation after oral administration?
  • True or false: When blood is collected, drug molecules are in the water portion of blood.
  • Which statement is true for zero-order elimination?
  • Which statement best describes the relationship between serum and plasma as described in the material?
  • On a concentration-time curve, which metric represents the total amount of drug absorbed systemically?
  • In first-order kinetics, how does the half-life respond to changes in dose?
  • Which sample is not listed as a data source for concentration-time profiling in the material?
Subscribe

Get the latest from Passetra

You can unsubscribe at any time. Read our privacy policy